| 引用本文: | 程昱,刘茂柏,王燕,阙万才,曾晓芳,陈茂华,丘宏强.血液系统恶性肿瘤患者伏立康唑谷浓度高变异性分析[J].中国现代应用药学,2020,37(17):2119-2123. |
| CHENG Yu,LIU Maobai,WANG Yan,QUE Wancai,ZENG Xiaofang,CHEN Maohua,QIU Hongqiang.Analysis of High Variability of Voriconazole Trough Concentration in Patients with Haematological Malignancies[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(17):2119-2123. |
|
| 摘要: |
| 目的 探讨影响血液系统恶性肿瘤患者伏立康唑谷浓度变异的潜在因素。方法 收集2015年11月—2017年9月进行伏立康唑治疗药物监测的血液系统恶性肿瘤患者的病史信息、临床资料、用药情况和实验室数据等，回顾性分析人口学、生理病理、合并用药、CYP2C19基因型等与标准化谷浓度的相关性。结果 研究最终纳入176例患者，241例监测数据，结果显示血液系统恶性肿瘤患者伏立康唑谷浓度存在较大变异。单因素和多因素Logistic回归分析结果显示CYP2C19*1/*1（快代谢型）是标准化谷浓度<1.0 mg·L-1的危险因素（OR：4.445，95%CI：1.514~38.449，P=0.015）；C反应蛋白（OR：2.377，95%CI：1.116~5.063，P=0.025）、合并使用奥美拉唑（OR：4.537，95%CI：1.716~14.637，P=0.018）及CYP2C19*2/*2，*2/*3和*3/*3（慢代谢型）（OR：10.199，95%CI：2.516~21.342，P=0.001）是伏立康唑标准化谷浓度>5.5 mg·L-1的危险因素。结论 血液系统恶性肿瘤患者伏立康唑谷浓度变异度高，影响因素多。CYP2C19基因型、合用奥美拉唑以及患者炎症水平可能是治疗时需考虑的因素。 |
| 关键词: 伏立康唑 治疗药物监测 谷浓度 血液系统恶性肿瘤 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.17.013 |
| 分类号:R969 |
| 基金项目:福建省科技创新联合资金项目（2017Y9036）；福建省卫生计生中青年骨干人才培养项目（2018-ZQN-35） |
|
| Analysis of High Variability of Voriconazole Trough Concentration in Patients with Haematological Malignancies |
|
CHENG Yu, LIU Maobai, WANG Yan, QUE Wancai, ZENG Xiaofang, CHEN Maohua, QIU Hongqiang
|
|
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, China
|
| Abstract: |
| OBJECTIVE To explore the potential factors associated with the variability of voriconazole trough concentration in patients with haematological malignancies. METHODS Medical history, clinical data, medication status and laboratory data of patients with haematological malignancies who underwent voriconazole therapeutic drug monitoring were retrospectively collected from November 2015 to September 2017. The correlation between normalized trough concentrations and demographics, physiological and pathology, drug combination, and CYP2C19 genotype was analyzed. RESULTS A total of 176 patients, 241 cases of monitoring data were included in the study. The results showed that voriconazole trough concentration in patients with haematological malignancies had high variability. Univariate and multivariate Logistic analysis suggested the CYP2C19*1/*1(extensive metabolizer) increased the risk of normalized trough concentration <1.0 mg·L-1(OR:4.445, 95%CI:1.514-38.449, P=0.015); While C-reactive protein(OR:2.377, 95%CI:1.116-5.063, P=0.025), combined with omeprazole(OR:4.537, 95%CI:1.716-14.637, P=0.018), and CYP2C19*2/*2, *2/*3 and *3/*3 (poor metabolizer)(OR:10.199, 95%CI:2.516-21.342, P=0.001) were risk factors of normalized trough concentration >5.5 mg·L-1. CONCLUSION Voriconazole trough concentration in patients with haematological malignancies has high variability and complicated factor. CYP2C19 genotype, concomitant with omeprazole, and inflammation should be considered in the treatment. |
| Key words: voriconazole therapeutic drug monitoring trough concentration haematological malignancies |
